Antimicrobial susceptibility testing of Campylobacter jejuni: a comparison between Etest and agar dilution method

The susceptibility of Campylobacter jejuni strains (n = 50) against nine antimicrobials were determined in comparison with Etest (AB BIODISK, Solna, Sweden) and agar dilution method to further investigate the correlation between the two methods. All the strains were isolated from stool samples of patients with diarrhea in 1998 and found to be highly susceptible (>84%) to ampicillin, tetracycline, gentamicin, chloramphenicol, ciprofloxacin and erythromycin. The essential agreement between two methods was 66.6% (+/- 1 1092 dilution) and 85.5% (+/-2 log(2) dilution), The agreement of susceptibility categories was higher at 94.4%. (C) 2003 Elsevier Science Inc. All rights reserved

Susceptibility of bacterial isolates from Turkey - A report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program

WOS: 000252617000005PubMed ID: 18230545The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum P-lactamase (ESBL) producers. Piperacillin/tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens

Susceptibility of bacterial isolates from Turkey - A report from the meropenem yearly susceptibility test information collection (MYSTIC) program

PubMedID: 18230545The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC 90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum ß-lactamase (ESBL) producers. Piperacillin/ tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens. © E.S.I.F.T. srl